Urogen Pharma (NASDAQ:URGN) Insider Sells $400,000.00 in Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider owned 119,763 shares in the company, valued at $4,790,520. The trade was a 7.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Schoenberg also recently made the following trade(s):

• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total value of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total value of $142,560.60.

Urogen Pharma Stock Performance

URGN opened at $38.56 on Monday. The company has a market capitalization of $1.88 billion, a price-to-earnings ratio of -14.02 and a beta of 1.56. Urogen Pharma has a 12-month low of $13.79 and a 12-month high of $40.35. The business’s fifty day simple moving average is $31.28 and its 200-day simple moving average is $24.44.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. On average, equities research analysts predict that Urogen Pharma will post -0.88 EPS for the current year.

Analyst Ratings Changes

URGN has been the subject of several research reports. Jefferies Financial Group raised shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating on shares of Urogen Pharma in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Finally, UBS Group reaffirmed a “buy” rating on shares of Urogen Pharma in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Institutional Trading of Urogen Pharma

A number of institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. raised its stake in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after acquiring an additional 3,070 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Urogen Pharma by 27.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock valued at $53,000 after acquiring an additional 486 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after acquiring an additional 3,125 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares during the last quarter. Finally, Nebula Research & Development LLC purchased a new position in Urogen Pharma in the second quarter worth $162,000. 91.29% of the stock is currently owned by institutional investors.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.